TY - JOUR
T1 - Diagnosis and Treatment of Neurocysticercosis
T2 - 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)
AU - White, A. Clinton
AU - Coyle, Christina M.
AU - Rajshekhar, Vedantam
AU - Singh, Gagandeep
AU - Hauser, W. Allen
AU - Mohanty, Aaron
AU - Garcia, Hector H.
AU - Nash, Theodore E.
N1 - Funding Information:
Potential conflicts of interest. The following list is a reflection of what has been reported to IDSA. To provide thorough transparency, IDSA requires full disclosure of all relationships, regardless of relevancy to the guideline topic. Evaluation of such relationships as potential conflicts of interest (COI) is determined by a review process that includes assessment by the SPGC Chair, the SPGC liaison to the development panel, the Board of Directors liaison to the SPGC, and, if necessary, the COI Task Force of the Board. This assessment of disclosed relationships for possible COI will be based on the relative weight of the financial relationship (ie, monetary amount) and the relevance of the relationship (ie, the degree to which an association might reasonably be interpreted by an independent observer as related to the topic or recommendation of consideration). The reader of these guidelines should be mindful of this when the list of disclosures is reviewed. For activities outside of the submitted work, A. C. W. has received royalties from UpToDate. For activities outside of the submitted work, A. H. has served as a member of a data and safety monitoring board for Neuropace. For activities outside of the submitted work, H. G. has received research grants from the National Institute of Neurological Disorders and Stroke and the Fogarty International Center of the National Institutes of Health. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Funding Information:
Financial support. Support for these guidelines was provided by the Infectious Diseases Society of America and the American Society of Tropical Medicine and Hygiene. This work was in part supported by intramural National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Publisher Copyright:
© The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
PY - 2018/4/3
Y1 - 2018/4/3
N2 - Gidelines for the clinical management of patients with neurocysticercosis (NCC) were prepared by a panel of the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). The guidelines are intended for infectious disease specialists, neurologists, neurological surgeons, internists, pediatricians, and family practitioners. These guidelines present our approaches to the diagnosis and management of patients with the different forms of neurocysticercosis,including viable parenchymal neurocysticercosis,single enhancing lesions, calcified parenchymal neurocysticercosis,ventricular neurocysticercosis, and subarachnoid neurocysticercosis. Our recommendations are based on the best evidence available. Due to the complex variations in clinical manifestations and the limitations of the literature, many of the recommendations are based on observational studies, anecdotal data, or expert opinion rather than randomized clinical trials. The approaches we describe are intended to be both applicable and feasible in the United States and Canada (for simplicity, referred to here as North America). The recommendations may not apply for settings where resource constraints may limit their applicability. The executive summary below lists the recommendations for the diagnosis and clinical management of neurocysticercosis. A detailed description of the methods, background, and evidence summaries that support each of the recommendations can be found online in the full text of the guidelines. A criterion for grading evidence is presented in Figure 1 [1]. Note that diagnosis and management of patients with neurocysticercosis can be challenging even with expert guidelines. Due to this complexity, clinicians with little experience with this disease should have a low threshold for consultation with an expert in the disease.
AB - Gidelines for the clinical management of patients with neurocysticercosis (NCC) were prepared by a panel of the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). The guidelines are intended for infectious disease specialists, neurologists, neurological surgeons, internists, pediatricians, and family practitioners. These guidelines present our approaches to the diagnosis and management of patients with the different forms of neurocysticercosis,including viable parenchymal neurocysticercosis,single enhancing lesions, calcified parenchymal neurocysticercosis,ventricular neurocysticercosis, and subarachnoid neurocysticercosis. Our recommendations are based on the best evidence available. Due to the complex variations in clinical manifestations and the limitations of the literature, many of the recommendations are based on observational studies, anecdotal data, or expert opinion rather than randomized clinical trials. The approaches we describe are intended to be both applicable and feasible in the United States and Canada (for simplicity, referred to here as North America). The recommendations may not apply for settings where resource constraints may limit their applicability. The executive summary below lists the recommendations for the diagnosis and clinical management of neurocysticercosis. A detailed description of the methods, background, and evidence summaries that support each of the recommendations can be found online in the full text of the guidelines. A criterion for grading evidence is presented in Figure 1 [1]. Note that diagnosis and management of patients with neurocysticercosis can be challenging even with expert guidelines. Due to this complexity, clinicians with little experience with this disease should have a low threshold for consultation with an expert in the disease.
KW - Taenia solium
KW - cysticercosis
KW - neurocysticersosis
KW - taeniasis
UR - http://www.scopus.com/inward/record.url?scp=85045142277&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045142277&partnerID=8YFLogxK
U2 - 10.1093/cid/cix1084
DO - 10.1093/cid/cix1084
M3 - Review article
C2 - 29481580
AN - SCOPUS:85045142277
SN - 1058-4838
VL - 66
SP - e49-e75
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 8
ER -